Starting from bisphenolic bis-styrylbenzene DF-9 (4), β-amyloid (Aβ) binding affinity and specificity for phenolic bis-styrylbenzenes, mono-styrylbenzenes and alkyne controls were determined by fluorescence titration with β-amyloid peptide Aβ 1-40 and a fluorescence assay using APP/PS1 transgenic mouse brain sections. Bis-styrylbenzene SAR is derived largely from work on symmetrical compounds; this study is the first to describe Aβ binding data for bis-styrylbenzenes unsymmetrical in the outer rings. With one exception, binding affinity and specificity were decreased by adding and/or changing the substitution pattern of phenol functional groups, changes to the orientation about the central phenyl ring, replacing the alkene with alkyne bonds, or elimination of the central phenyl ring. The only compound with an Aβ binding affinity and specificity comparable to 4 was its 3-hydroxy regioisomer 8. Like 4, 8 crossed the blood-brainbarrier and bound to Aβ plaques in vivo. Using a DPPH assay, phenol functional groups with para orientations seem to be a necessary, but insufficient, criterion for good free radical scavenging properties in these compounds.
shown to penetrate the blood -brain barrier (BBB) and bind to Aβ plaques deposited in APP or APP/PS1 mice. 11 As shown by K114 (3) and DF-9 (4), acidic functional groups are not necessary for good Aβ binding. 12, 13 Several stilbene-based compounds, such as SB-13 and BAY94-9172, have been studied for early detection in AD. 14, 15 While the structure-activity relationship (SAR) of bis-styrylbenzene compounds has been extensively investigated, the common thread in these studies is that Aβ-binding SAR has been elucidated based largely on symmetrical bis-styrylbenzenes.
Design
Previously, we showed that the bis-styrylbenzene, (E,E)-1,4-bis(4-hydroxystyryl) benzene (4) , binds to Aβ with high affinity and specificity. 13 In recent years, many 16, 17 have recognized the antioxidant and potential anti-AD properties of the polyphenolic styrylbenzene (stilbene) resveratrol (5), a well-known component of red wine. Therefore, we also included structural elements of 5 in the design of target compounds (Figure 1 ), especially since oxidative stress is considered to play an important role in AD pathology. 18 Little has been studied regarding substitution patterns in the central benzene ring of Aβ-binding bis-styrylbenzenes. For this purpose we designed target compounds 6 and 7 with a 1,3 and 1,2 orientation about the central benzene ring as opposed to the more extended 1,4 orientation in 4 and other reported bis-styrylbenzenes. 11, 12 Target compounds 8 and 9 are the meta and ortho bis-phenolic regioisomers of 4. Tetraphenol 10 is a symmetrical bisstyrylbenzene that combines the resorcinol substructures of 5. Unsymmetrical target compounds 11-15 contain from one to three phenol functional groups, but each maintains at least one of the para phenols of prototype 4. The final target compounds are the mono-styryl (16) and bis-alkyne (17) derivatives of 4. A secondary objective in designing these unsymmetrical bis-styrylbenzenes was an attempt to increase the solubility of this class of compounds as we have observed that symmetrical bis-styrylbenzenes have poor aqueous solubilities. For each target compound, we determined Aβ-binding affinity and specificity and antioxidant properties in addition to BBB penetration for selected compounds. We suggest that these data will be useful in the design and discovery of new early diagnosis probes for AD using PET, SPECT or MRI and potentially for AD therapeutics.
Chemistry
Compounds 4 13 and 6-10 (Scheme 1) were obtained using a previously reported procedure. 13 The preparation for 6 was an improvement on the previously published procedure 19 for this compound in which a low-yielding (20%) double-Heck coupling was used. The overall yields of 8 (69%) and 10 (42%) were better than those (49 and 28%) previously reported 20, 21 for these compounds. 1,3-and 1,2-Bis(diethylphosphonylmethyl)benzenes 19b (96%) and 19c (93%) were synthesized using the Arbuzov reaction with o-and m-xylylene dibromide. Bis-diethylphosphonates 19a-19c were coupled with methoxymethoxy (MOM)-substituted benzaldehydes 20a-20d to afford 4a and 6a-10a in 48-84% yields, which were then deprotected to afford 4 and 6-10 in 64-99% yields.
Compounds 11-15 (Scheme 2) were synthesized via successive Heck and HornerWadsworth-Emmons reactions using a new one-pot procedure. 22 Heck couplings between 4-iodobenzyl phosphonate (21) and styrenes 22a-22c were accomplished with palladium(II) acetate, phenylurea and potassium carbonate in DMF at 110 °C for 22 h. 22 The reaction mixtures were cooled to 80 °C followed by addition of benzaldehydes 20a, 20b, 20d or 20e and 30% w/v sodium methoxide in MeOH and then stirred for an additional 1 h to afford 11a-15a in 52-79% yield. HCl deprotection of 11a-15a afforded 11-15 in 70 -94% yield after filtration and washing. Although 11 was previously synthesized in 31% overall yield in a five-step procedure, 24 we were able to synthesize this same compound in 73% overall yield using this new one-pot method. Compounds 16 and 17 were synthesized by modified literature 25, 26 procedures (see Supporting Information).
β-Amyloid (Aβ) Binding Affinity and Specificity β-Amyloid (Aβ) binding affinity and specificity for bis-styrylbenzenes 6-17, with 4 and 5 as controls, were determined by means of fluorescent titrations 27 with aggregated amyloid peptide Aβ and an in vitro fluorescence-based assay using APP/PS1 transgenic mouse brain sections. 13 The APP/PS1 transgenic mice were developed by crossing the Tg2576 strain, 28 which express the K670N/M671L mutant of APP695 found as the Swedish familial AD gene, and the M146L 6.1 strain, 29 which express the M146L mutant of PS1 found as the early onset familial AD gene. The specificity is determined by measuring the fluorescent intensity of Aβ plaques (specific signal) compared to that of background normal brain tissue (noise) (Figure 2 ).
The only compound with an Aβ binding affinity and specificity comparable to that of 4 was its 3-hydroxy regioisomer 8, which had a measured K d of 5.3 ± 0.3 nM and a specificity of 9.6 ± 3.0 (Table 1) . In contrast, 9, the 2-hydroxy regioisomer of 4, had an 84-fold weaker Aβ binding affinity, although it had good binding specificity. Apparently, the 1,4 orientation about the central benzene ring in compounds 4, 8, and 9 endows them with the extended geometry required to maintain strong binding interactions in the hydrophobic binding site(s) of the Aβ fibril, but only 4 and 8 have the required phenol functional group orientations to potentially form strong H-bonding interactions. However, 12, the unsymmetrical regioisomeric hybrid of 4 and 8, had an unexpectedly much weaker Aβ binding affinity (370 and 660-fold) compared to that of 4 and 8.
The two order of magnitude decrease in Aβ binding affinity for 6 and 7 show that the optimal geometry about the central benzene ring is a 1,4 orientation as opposed to 1,3 (6) or 1,2 (7). Even though the anti-aggregation properties of 1,3-bis-styrylpyridines and 1,3-bisstyrylbenzenes 30 and Aβ-binding properties of 1,3-bis-styrylquinaldines 31 have been investigated, this is the first time that Aβ-binding affinity and specificity has been assessed as a function of the central ring substitution pattern of bis-styrylbenzenes.
As evidenced by the 17 to 27-fold loss in Aβ binding affinity for the more polar tetraphenol 10 and triphenols 13 and 14, additional phenol functional groups decreased affinity and tended to decrease specificity. Compared to bis-phenol 4, mono-phenol 11 showed a 16-fold reduction in binding affinity, due most likely to the loss of a H-bond formed by the second phenol functional group in 4. Compared to 4, the more rigid linear alkyne analog 17 had a 6-fold loss in Aβ binding affinity and a 2.4-fold loss in specificity, due possibly to an inability to attain a conformer orientation complementary to the Aβ fibril surface. Of all of the target compounds, the symmetrical mono-styrylbenzene 16 had the weakest Aβ binding affinitythree orders of magnitude weaker than that of 4. This could be attributed either to the loss of the central benzene ring eliminating a critical binding interaction, or to the shorter distance between phenol functional groups, reducing the effectiveness of 16 to form strong H-bonds with the Aβ fibril surface, or a combination of the two. Surprisingly, mono-styrylbenzene 5 displayed only a 52-fold loss in binding affinity compared to 4. Conceivably, the 3,5-dihydroxy substituted 5, but not the 4-hydroxy substituted 16, provides conformers with the geometry required to form strong H-bonds to the aggregated Aβ fibril.
Human AD Brain Section Staining
Bis-styrylbenzenes 8 and 10, along with the control bis-styrylbenzene 4, were used to stain human AD brain sections (Figure 2) . Each compound was shown to bind specifically to Aβ plaques in human brain sections. Age matched controls were also stained and showed no staining of normal brain tissue (data not shown).
In Vivo BBB Delivery in Plaque-Bearing Mice
We next determined whether interperitoneally administered 8 and 10 (with 4 as a control) could cross the BBB and bind to Aβ plaques. Bisstyrylbenzenes 4, 8 and 10 (50 mg/kg) were injected into ten-month-old plate-derived growth factor-β chain promoter driving APP (PDAPP) transgenic mice. As shown in Figure 3 , all compounds crossed the BBB and bound to Aβ plaques in vivo. Each section showed intense Aβ plaque signals with high specificities. Control non-transgenic animals showed no specific signals in the brain for any of the tested compounds after intraperitoneal injection (data not shown). These data confirm that these bis-styrylbenzene derivatives retain the BBB penetration capabilities of 4, and that 8 and 10 have the potential as lead compounds for early Aβ detection research.
Free Radical Scavenging Activity
The relative free radical scavenging properties of the target bis-styrylbenzenes, along with quercetin as a control, were measured using the stable free radical 1,1-diphenyl-2-picrylhydrazyl (DPPH) following the procedure of Yang et al. 32 with some modifications (Table 2) . Compound 4, 6, 12, and 16 were no less effective than quercetin (IC 50 = 1.3 ± 1.1 μM) in DPPH free radical scavenging activity, whereas compounds 7, 9, 10, 14 and 15 were 3 to 7-fold less potent (p < 0.05) than quercetin. Aside from 8 and 13, which had no antioxidant activity (IC 50s > 100 μM) in this assay, mono-styrylbenzene 5 and bis-alkyne 17 were the least effective radical scavengers with IC 50 s of 62 and 45 μM, respectively. No particular SAR is apparent from these data aside from the general observation that a phenol functional group with a para orientation seem to be a necessary, but insufficient, criterion for good free radical scavenging properties of bis-styrylbenzenes. With polyphenolic antioxidants such as 5 17 of increasing interest in AD research, this set of compounds may prove beneficial in future research.
Summary
These data extend the SAR of bis-styrylbenzene Aβ binding and free-radical scavenging activity and provide further direction for the development of non-invasive Aβ binding ligands for early detection of AD. One new bis-styrylbenzene prototype (8) was identified that could serve as a building block for the design and discovery of new early diagnosis probes for AD using PET, SPECT or MRI and potentially for AD therapeutics. Finally, we observed that a phenol functional group with a para orientation seem to be a necessary, but insufficient, criterion for good free radical scavenging properties in these bis-styrylbenzenes.
Experimental Section General
Starting materials were purchased from Aldrich, TCI or Acros. All reactions were run under a positive pressure of Ar. Melting points were determined on a Stanford Research Systems E-Z Melt apparatus and are uncorrected. 1 H (500 MHz) and 13 C (125.7 MHz) NMR spectra were measured on a Varian spectrometer using CDCl 3 and DMSO-d 6 as solvents. All chemical shifts are reported in parts per million (ppm) and are relative to internal (CH 3 ) 4 Si for 1 H, CDCl 3 (77.0 ppm) and DMSO-d 6 (39.7 ppm) for 13 C NMR. Elemental analyses were performed by M-H-W Laboratories, Phoenix, AZ. All target compounds had purities ≥ 95%.
(E,E)-1,4-bis(4-hydroxystyryl)benzene (4) 13
Step 1. A 30 wt % solution of sodium methoxide in methanol (1.39 mL, 7.40 mmol) was added to a stirred mixture of 20a (0.983 g, 5.92 mmol) and 1,4-bis(diethylphosphonylmethyl)benzene (19a) (1.12 g, 2.96 mmol) in DMF (15 mL) at rt. This mixture was heated to 80 °C for 2 h. The reaction was then quenched with H 2 O (10 mL) and the solid precipitate was filtered and rinsed with ether to afford (E,E)-1,4-bis-(4-methoxymethoxy)styrylbenzene 4a (0.858 g, 72%). 1 (E,E)-1,4-bis(3-hydroxystyryl)benzene (8). 19 Step (E,E)-1,4-bis(2-hydroxystyryl)benzene (9). 33 Step 1. As described above for 4a, 20c (1.05 g, 6.31 mmol) and 19a (1.19 g, 3 
(E,E)-1,4-bis(3,5-dihydroxystyryl)benzene (10). 21
Step 1 (E,E)-1-styryl-4-(4-hydroxystyryl)benzene (11). 22 As described above for 4, 11a (0.654 g, 1.91 mmol) was deprotected using 12.0 M HCl (1.05 mL, 12.6 mmol) to afford 11 (0.53 g, 93%): mp 281 -285 °C. 1 
(E,E)-1-styryl-4-[4-(methoxymethoxy)styryl]benzene (11a). 22
Diethyl 4-iodobenzyl phosphonate (21) (0.414 g, 1.17 mmol) and 22a (0.260 g, 2.34 mmol) were mixed with palladium (II) acetate (0.008 g, 0.035 mmol), phenylurea (0.010 g, 0.070 mmol) and potassium carbonate (0.323 g, 2.34 mmol) in DMF (5 mL) and stirred at 110 °C for 22 h. The reaction temperature was then cooled to 80 °C and to this mixture were added 20a (0.195 g, 1.17 mmol) and 30% w/v sodium methoxide in methanol (0.440 mL, 2.34 mmol). The reaction was stirred for 1 h at 80 °C and then cooled to rt and quenched with H 2 O (15 mL). The solid was then filtered and rinsed with H 2 O and ether to afford 11a (0.317 g, 79%): m.p. 240 -243 °C. 1 (E,E)-1-(4-hydroxystyryl)-4-(3-hydroxystyryl) 127.1, 128.1, 128.3, 128.6, 129.8, 135.9, 137.1, 138.7, 157.6, 157.8.   (E,E)-1-[4-(methoxymethoxy)styryl]-4-[3-(methoxymethoxy)styryl}benzene (12a) As described above for 11a, 21 (0.312 g, 0.880 mmol), 22b (0.289 g, 1.76 mmol) were mixed with palladium (II) acetate (0.006 g, 0.03 mmol), phenylurea (0.007 g, 0.05 mmol) and potassium carbonate (0.243 g, 1.76 mmol) and stirred for 22 h at 110 °C in DMF. After cooling to 80 °C, compound 20b (0.146 g, 0.880 mmol) and sodium methoxide solution (0.330 mL, 1.76 mmol) were added and the reaction was stirred for 1 h at 80 °C and worked up as described above to yield 12a (0.23 g, 65%): mp 142 -152 °C. 1 
(E,E)-1-(4-hydroxystyryl)-4-(3,4-dihydroxystyryl)benzene (13)
As described above for 4, 13a (0.100 g, 0.216 mmol) was deprotected using 12. -d 6 ) δ 102.5, 104.9, 115.8, 125.0, 126.6, 127.0, 127.8, 128.1, 128.4, 128.6, 128.7 , 135.9, 137.1, 139.1, 157.6, 158.8.
(E,E)-1-[4-(methoxymethoxy)styryl]-4-[3,5-di(methoxymethoxy)styryl]benzene (14a)
As described above for 11a, 21 (0.342 g, 0.965 mmol), 22b (0.317 g, 1.93 mmol) were mixed with palladium (II) acetate (0.007 g, 0.03 mmol), phenylurea (0.008 g, 0.06 mmol) and potassium carbonate (0.267 g, 1.93 mmol) and stirred for 22 h at 110 °C in DMF. After cooling to 80 °C, compound 20d (0.218 g, 0.965 mmol) and sodium methoxide solution (0.362 mL, 1.93 mmol) were added and the reaction was stirred for 1 h at 80 °C and worked up as described above to yield 14a (0.285 g, 64%): mp 114 -119 °C. 1 E)-1-(3-hydroxystyryl)-4-(3,4-dihydroxystyryl) In Vitro A Plaque Binding Specificity Using APP/PS1 Transgenic Mouse Brain Slices DMSO stock solutions of 4-17 were diluted to 0.50 mM with EtOH and then diluted with 9:1 PBS:EtOH to prepare 50 μM solutions. Eleven-month old transgenic APP/PS1 mice derived from crossing the Tg2576 line expressing APP Swedish mutant and the M146L 6.1 line expressing presenilin-1 mutant 28, 29 were anesthetized and transcardially perfused with 4% paraformaldehyde in PBS under the guidance of Institutional Animal Care and Use Committee at the University of Nebraska Medical Center. Fixed brains samples were cryoprotected in 20% sucrose in PBS and subjected to cryostat sectioning (Leica). Frozen brain sections (10 μm thickness) of aged APP/PS1 transgenic mice (three sections per dilution point) were stained with compound solutions for 30 min, and then washed successively with 75% aq. EtOH, 95% aq EtOH and xylene. Fluorescence imaging of the stained and washed brain sections were carried out using a DAPI filter (Chroma) and a Roper HQ CCD camera (original magnification: 400x) following a standard FSB staining protocol. 34 Fluorescence images of three plaques per section were systematically captured using the same image acquisition setting (laser power, capturing time, photomultiplier setting) to obtain comparable fluorescent intensities of five plaque regions (specific signal) and five background regions (noise signal) to calculate signal-to-noise (S/N) ratios.
Fluorescence Staining of AD and Control Brain Sections by 4, 8 and 10
Human adult AD brain sections and age-matched controls were stained with compounds 4, 8 and 10. The frozen brain sections (10 μm thickness) were stained with compound solutions (same concentrations and PBS:EtOH content as mouse brain section staining solutions) for 30 min and then washed successively with 75% aq. EtOH, 95% ethanol and xylene. Fluorescence imaging was performed as described in the previous section.
In Vivo BBB Delivery of 4, 8 and 10 to A β Plaque-Bearing PDAPP Mouse Brain
Ten-month-old plate-derived growth factor-β chain promoter driving (PDAPP) mice were injected intraperitoneally (IP) with vehicle only (10% DMSO/PBS) or with single 50 mg/kg doses IP of 4, 8, or 10, and sacrificed at 48 h after injection by transcardial perfusion with 4% paraformaldehyde (PFA) in PBS. After cryoprotection, fixed frozen brains were sectioned with 30 mm thickness, postfixed with 4% PFA for 5 min., washed in PBS, and mounted on microscope slides with coverslips using Vectorshield mounting medium (Vector Laboratories, Burlingame, CA). Fluorescence images were captured with a digital Olympus DP71 camera (Olympus, Center Valley, PA) connected to a TE-300 microscope (Nikon, Garden City, NJ).
DPPH Free Radical Scavenging Assay
Relative free radical quenching for 4-17, along with quercetin as a control, was assayed spectrophotometrically using the stable free radical 1,1-diphenyl-2-picrylhydrazyl (DPPH) following the procedure of Yang et al. 32, 34 with some modifications. Abstraction of a proton from a free radical scavenger (target compound) decreases the DPPH absorption at 517 nm. Reactions were run in a 96-well plate and the absorbance at 517 nm was recorded on a plate reader. All compounds were first solublized in DMSO to form concentrated stock solutions (~15 mM) that were then diluted into working solutions in MeOH. Mixtures in the wells contained increasing concentrations of target compounds (0 nM-5 mM), 100 μM DPPH and MeOH (300 μL total volume). Each concentration was performed in triplicate and IC 50 
